Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a common diabetes pill stop dangerous side effects in type 1 patients?

NCT ID NCT07056699

First seen Nov 11, 2025 · Last updated May 21, 2026 · Updated 27 times

Summary

This study looks at whether adding pioglitazone (a type 2 diabetes drug) can block harmful side effects caused by dapagliflozin in people with type 1 diabetes. Dapagliflozin can increase liver glucose, fat breakdown, and ketone production, which may lead to a dangerous condition called ketoacidosis. The study will involve 24 adults with type 1 diabetes and will measure changes over 16 weeks using special tracers and blood tests.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE1DIABETES are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Texas Diabetes Institute

    San Antonio, Texas, 78229-3900, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.